Filing Flows › Sutro Biopharma (STRO) › Q2 2025
Sutro Biopharma (STRO) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 7, 2025
Sutro Biopharma (STRO) reported revenue of $63.7M for the second quarter 2025 (Q2 2025), +148% from a year earlier and +266% from the quarter before. Operating margin was -5.2%, net loss $11.5M (18.0% of revenue).
Sutro Biopharma, Q2 2025: revenue $63.7M (+148% year over year), operating margin -5.2%, net loss $11.5M, operating cash flow −$44.7M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $63.7M | +266% | +148% |
| Operating profit | −$3.3M | — | — |
| Net earnings | −$11.5M | — | — |
| Operating cash flow | −$44.7M | — | — |
What changed
Revenue was $63.7M in Q2 2025, up 148% year over year and up 266% from the previous quarter.
Operating costs exceeded revenue by $3.3M, an operating margin of -5.2%. Total costs fell 10% while revenue rose 148%. The quarter ended with a net loss of $11.5M, narrower than the previous quarter's $76.0M loss. Net interest and other expense of $8.2M was the main reason.
Operating cash flow was −$44.7M. Non-cash charges added back $1.9M of depreciation and amortization and $5.3M of share-based compensation. Working capital and other items used $40.4M.
Questions
What was Sutro Biopharma's revenue in the second quarter 2025?
Sutro Biopharma (STRO) reported revenue of $63.7M for the second quarter 2025 (Q2 2025), +148% from a year earlier and +266% from the quarter before.
Was Sutro Biopharma profitable in the second quarter 2025?
Operating loss was $3.3M (-5.2% of revenue) and net loss $11.5M.
Source: Sutro Biopharma 10-Q on SEC EDGAR.